RESULTS: There were 190 (18.3%) cases involving oxycodone. The majority of these decedents were male (70.5%) and white (96.8%), with an average age of 39.2 ( 10.1) years and an average BMI of 29.7 ( 7.5). Approximately 84% of the oxycodone cases had at least one additional drug contributing to death, with diazepam (27.9%), hydrocodone (23.2%), alprazolam (20.0%), and ethanol (14.2%) being identifi ed most commonly. Nearly two-thirds of cases had an existing condition considered non-contributory to death, with a history of substance abuse (38.4%), cardiovascular disease (32.6%), and head and central nervous system disease (22.6%) occurring most frequently. In 92% of the oxycodone cases, oxycodone was considered to play a direct role in death. The manner of death of most oxycodone cases was classifi ed as accidental (91.7%), with only 3.9% classifi ed as suicide. CONCLUSIONS: Concomitant drug use was a common fi nding in oxycodone-related deaths in West Virginia. This study highlights the importance of health care professionals talking to patients about potential dangers associated with combined drug misuse or abuse and to use caution when prescribing oxycodone with other drugs, especially controlled substances, for individuals with a history of substance abuse.
PSY2 HOW WELL DOES BODY MASS INDEX PREDICT WAIST CIRCUMFERENCE FOR PATIENTS WITH METABOLIC SYNDROME?
Liu G 1 , Luo N 2 , McCollam PL 3 , Xie Y 4 1 Peking University, Beijing, China, 2 National University of Singapore, Singapore, Singapore, 3 Eli Lilly and Company, Indianapolis, IN, USA, 4 University of Iowa, Iowa City, IA, USA OBJECTIVES: To examine the association between waist circumference and body mass index in patients with metabolic syndrome. METHODS: Based on a large electronic medical record database, all adult patients were identifi ed for metabolic syndrome using the guidelines by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). The waist circumference (WC) was regressed as a linear function of body mass index (BMI) while controlling for individual age, gender, and identifi ed latent classes of metabolic risk factors. RESULTS: A total of 18,788 patients with metabolic syndrome were identifi ed from the database. The mean (standard deviation) age is 57.2 (13.9), with 51.3% being females. The prevalence of abnormal triglycerides (TG; 150 mg/dL), high-density lipoprotein cholesterol (HDL-C; men: 40 mg/dL; women: 50 mg/dL), blood pressure (BP; systolic 130 mmHg, diastolic 85 mmHg, or drug treatment for hypertension), fasting plasma glucose ( 100 mg/dL or drug treatment for diabetes mellitus), and waist circumference (WC; men: 102 cm; women: 88 cm) was 79.6%, 74.3%, 96.4%, 69.2%, and 81.4%, respectively. The Pearson's correlation between WC and BMI is 0.68. In a linear regression model only controlling for age and gender, it is found that one unit increase in BMI is associated with 0.68 inches more in WC (p 0.001). BMI, age and gender together explains 54.5% of the variation in WC. The positive relationship between WC and BMI still remains highly signifi cant and changes little numerically, after including fi ve latent classes of metabolic risk conditions. CONCLUSIONS: For patients with metabolic syndrome, there is a strong and positive association between waist circumference and body mass index, which remains robust after controlling for unobserved metabolic risk conditions.
PSY3

BURDEN OF OBESITY AND ASSOCIATED TREATMENT PATTERNS IN EUROPE: A COMPARISON OF FIVE COUNTRIES
Narayanan S y 1 , Potthoff P 2 , Guether B 2 1 TNS Healthcare, New York, NY, USA, 2 TNS Healthcare, Munich, Bavaria, Germany OBJECTIVES: To assess burden of obesity and associated treatment patterns among fi ve European nations. METHODS: TNS European Healthcare Panel of individuals in France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess disease burden at national level, to build an epidemiological database in these 5 countries. The data is representative of population gender and age strata in respective countries, ensured by sampling and intensive panel management. The survey collected information on select health conditions (incl. obesity, defi ned as BMI 30; in the past 12-months), quality of life and health care-utilization. RESULTS: In the TNS European Healthcare Panel, 8, 665, 25, 265, 19, 887, 59, 850 and 47, 340 (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) yrs: % individuals) as follows: Italy: 5.1%,8.0%,13.8%,18.6%,23.6%,22.2%; France: 5.9%,9.8%, 17.3%,20.2%,27.1%,28.8%; the Netherlands: 6.5%,8.8%,21.5%,25.6%,29.8%, 28.0%; Germany: 8.3%,12.2%,22.8%,28.7%,34.2%,30.9%; U.K: 13.5%,18.0%, 28.5%,34.7%,39.4%,37.9%. Anti-obesity medications were used by 7.2%,8.0%, 10.1%,13.7%,16.1% of obese individuals in the Netherlands/Germany/U.K/France/ Italy respectively. In absolute terms, over 12.7 million individuals in the fi ve countries had taken an obesity reducing product in the last year, with France leading the list ( 3.7 million). CONCLUSIONS: Obesity disease burden appear to be substantial and increased with age. Treatment with anti-obesity products varied across the fi ve countries and did not appear to be proportional to the disease burden in the respective countries. Closer scrutiny is warranted to assess current practices to alleviate disease burden in respective geographies.
PSY4 THE USE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY DATA TO UNDERSTAND DIFFERENCES IN RECOMBINANT FACTOR VIIA (RFVIIA) DOSING AND CLINICAL OUTCOMES FOR SPECIFIC JOINT HEMORRHAGES IN HEMOPHILIA
Valentino LA 1 , Cooper DL 2 1 Rush University and Rush Children's Hospital, Chicago, IL, USA, 2 Novo Nordisk, Inc., Princeton, NJ, USA OBJECTIVES: Frequent bleeding episodes within joints (hemarthrosis) in patients with congenital hemophilia with alloantibody inhibitors (CHwI) can result in the development of target joints with eventual functional disability. Clinical trials have assessed the effi cacy of rFVIIa in the treatment of hemarthroses. Such studies have not been designed to address whether specifi c joints are more diffi cult to treat. The HTRS Registry is a collaborative effort between HTRS and Novo Nordisk to understand the effi cacy and safety of rFVIIa and expand knowledge about treatment of hemophilia. METHODS: We analyzed data from 2041 rFVIIa-treated bleeds in the HTRS registry (January 2004 -November 2008 to identify hemarthroses in patients with CHwI. RESULTS: There were 1163 hemarthroses treated with rFVIIa (fi rst line:1,065, second line:98). Median age at time of bleed was 9 yrs (range:0-60). The 798 non-target (NT) and 344 target (T) joint bleeds included (NT/T): ankle (279/169); elbow (202/90); knee (143/76); shoulder (46/5); foot (45/1); wrist (43/1); hand (43/0) and hip (24/4). Median (range) total rFVIIa dose per treatment episode for non-target joints was 400 mcg/kg (46-18130 mcg/kg) and for target joints was 630 mcg/kg (50-21392 mcg/ kg). Total dosing varied by joint and was higher for target joints (NT/T): ankle (300/650); knee (360/558); elbow (490/556); hip (494/884); shoulder (720/1080). Overall effi cacy for all joint bleeds was 90%, and for target joints was 90%. CON-CLUSIONS: For rare disorders, such as congenital hemophilia with inhibitors, obtaining evidence-based outcomes for data subsets through clinical trials is not always practical. The HTRS registry provides another large dataset and allows for comparison of clinically effective dosing regimens for treatment of non-target/target joints and across different joints. The data shown have implications for the design of future trials and in the analysis of trial results to account for variability in different joint bleeds between trial arms.
PSY5 THE USEFULNESS OF REGISTRY DATA FOR UNDERSTANDING TREATMENT PRACTICES AND CLINICAL OUTCOMES IN HEMOPHILIA: THE EXPERIENCE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY (2004-2008)
Kessler CM 1 , Gill JC 2 , Cooper DL 3 1 Georgetown University Medical Center, Washington, DC, USA, 2 Medical College of Wisconsin, Milwaukee, WI, USA, 3 Novo Nordisk, Inc., Princeton, NJ, USA OBJECTIVES: This study evaluates the HTRS registry, developed as a collaboration to support the society research and a company post-marketing surveillance requirement for recombinant FVIIa in patients with congential hemophilia (CH) with alloantibody inhibitors (CHwI). METHODS: The HTRS registry is a web-based second generation database. After IRB approval and informed consents, 83 sites participated in the registry from January 2004 to November 2008. RESULTS: There are 2484 patients registered including 1696 with congenital hemophilia A or B. Median age was 13 years (range:0-85) for CH and 12 years (range:0-83) for CHwI. Non-Hispanic whites (CH:68%,CHwI:57%) and non-Hispanic blacks (CH:16%, CHwI:23%) were the largest racial/ethnic groups. The majority had little or no functional limitations (CH:77%, CHwI:66%). For CHwI patients, the median highest anti-VIII titers were 48BU (human) and 16BU (porcine). There were 6,517 acute bleeds captured (CHwI:6,025, rFVIIa:2,207). Acute bleed data was available for 429 CHwI patients, including 2,041 rFVIIa-treated bleeding episodes (fi rst line:1851, second line:190). Approximately, 57% were spontaneous, 30% traumatic, 3% surgical, and 2% dental procedures. Bleeds were most frequent in joints (57%, 1163 bleeds), including ankle (448), knee (219) and elbow (292) bleeds. Others included muscle (20%), mucosal (7%), subcutaneous (6%), and head (3%). Median (range) total rFVIIa dose per treatment episode was 450 mcg/kg (46-43200 mcg/kg), with initial dose of 120 mcg/ kg (37-400 mcg/kg), and 3 injections (1-480) over 1 day (1-99). Overall effi cacy was 90%. Adverse events were rare. CONCLUSIONS: For rare disorders, such as hemophilia complicated by alloantibody inhibitors, obtaining evidence-based outcomes through clinical trials is not always practical or statistically conclusive. The analysis of the signifi cant amount of data accumulated over a 4-year period in the HTRS database represents an alternative approach to understanding the safety and effi cacy of new therapeutic agents through the analysis of the "collective" experience of patients included in a longitudinal database.
